Neurodegeneration, oxidative stress and lipid metabolism plasma biomarkers to differentiate Parkinson's disease from atypical parkinsonian syndromes.

Date publication

juin 2023

Journal

Revue neurologique

Auteurs

Membres identifiés du Cancéropôle Est :
Dr LIZARD Gérard , Dr PAIS DE BARROS Jean-Paul

Tous les auteurs :
Schneider V, Vejux A, Nury T, Dupont G, Pais de Barros JP, Lakomy D, Lizard G, Moreau T

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/37328356

Résumé

The identification of blood biomarkers appears to be a means of improving diagnosis accuracy in Parkinson's disease (PD) and atypical parkinsonian syndromes (APS). We, therefore, evaluate the performance of neurodegeneration, oxidative stress and lipid metabolism plasma biomarkers to distinguish PD from APS.

Mots clés

Atypical parkinsonian syndromes, Lipid metabolism, Neurodegeneration, Oxidative stress, Parkinson's disease, Plasma biomarkers

Référence

Rev Neurol (Paris). 2023 06 14;: